Preclinical models for cell cycle-targeted therapies.
Deregulation of the cell cycle machinery is frequently associated to tumor development in most cell types. Many of these tumor-associated alterations result in the abnormal activation of cyclin-dependent protein kinases (Cdks) involved in the G1/S transition. Recent results from the genetic analysis of cyclins and Cdks in mouse models have raised some questions regarding the relevance of these molecules in cell cycle-targeted strategies for cancer therapy. The comprehensive evaluation of these biochemical and genetic data seems to be a necessary given the relevance of these and other new cell cycle kinases as targets for therapeutic approaches in cancer.
Malumbres
Marcos
M
Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
D000818:Animals; D002453:Cell Cycle / Q000502:physiology; D018797:Cell Cycle Proteins / Q000502:physiology*; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000503:physiopathology* / Q000628:therapy*
D018797:Cell Cycle Proteins